Stephan Tanda

President, Chief Executive Officer & Executive Director, Aptargroup

Search every verified Stephan Tanda interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Stephan Tanda, President and CEO of AptarGroup, has discussed the company's performance and market conditions in several media appearances. In late 2024, he stated that supply chain issues were "in the rear view mirror" and that the company was "back to executing very well." He described the company's portfolio as "a very broad portfolio" but noted that all its factories perform "high-speed assembly" and that the technology can be leveraged across different sectors. Tanda characterized the impact of potential tariffs on the company as "neutral," citing a philosophy of "serving the region from within the region." He attributed recent weakness in the U.S. food and personal care segments to "a supply chain effect coming out of COVID" and inventory adjustments by customers and retailers. Tanda also noted that the company supplies components for three GLP-1 drugs on the market and is investing over $180 million in capacity for biologic drugs. In a 2022 interview, Tanda said that on any given day the company was missing about 15% of its workforce, stating that "there is just not enough people who are interested in a career in manufacturing." He said the company had raised wages by 30% and offered benefits, but that it was "just not enough." In a 2026 webinar, Tanda discussed the CEO/CHRO partnership as a driver of culture, stating that the company's mantra is "think and win locally and leverage globally." Earlier in his career at DSM, Tanda spoke about the need for a transition to a bio-based economy, arguing that "the private sector is a partner in making this happen" in addressing malnutrition and building resilient food systems.